Teaching moment: Why promising biomarkers do not always translate into clinically useful tests

Journal of Clinical Oncology

Volumn 32, Issue 4, 2014, Pages 359-361

  Castle, Philip E ^a  

^a Global Cancer Initiative   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY;

FEMALE; HEAD AND NECK TUMOR; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; ISOLATION AND PURIFICATION; MALE; NOTE; PAPILLOMAVIRUS INFECTION; VIROLOGY;

ANTIBODIES, VIRAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; MALE; PAPILLOMAVIRUS INFECTIONS;

EID: 84897018555     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.52.3076     Document Type: Letter

References (11)

1. Kreimer AR, Johansson M, Waterboer T, et al: Evaluation of human papillomavirus antibodies and risk of subsequent head and neck cancer. J Clin Oncol 31:2708-2715, 2013
2. Zandberg DP, Bhargava R, Badin S, et al: The role of human papillomavirus in nongenital cancers. CA Cancer J Clin 63:57-81, 2013
3. Chaturvedi AK, Engels EA, Anderson WF, et al: Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol 26:612-619, 2008 (Pubitemid 351264356)
4. Saslow D, Solomon D, Lawson HW, et al: American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. CA Cancer J Clin 62:147-172, 2012
5. Moyer VA: U.S. Preventive Services Task Force: Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 156:880-891, W312, 2012
6. Castle PE: Re: Human papillomavirus in oral exfoliated cells and risk of head and neck cancer. J Natl Cancer Inst 96:1181-1182; author reply 1182-1183, 2004
7. Fakhry C, Rosenthal BT, Clark DP, et al: Associations between oral HPV16 infection and cytopathology: Evaluation of an oropharyngeal "pap-test equivalent" in high-risk populations. Cancer Prev Res (Phila) 4:1378-1384, 2011
8. Kreimer AR: Prospects for prevention of HPV-driven oropharynx cancer. Oral Oncol [epub ahead of print on July 19, 2013]
9. Wentzensen N, Wacholder S: From differences in means between cases and controls to risk stratification: A business plan for biomarker development. Cancer Discov 3:148-157, 2013
10. Ang KK, Harris J, Wheeler R, et al: Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24-35, 2010
11. Pepe MS, Janes H, Longton G, et al: Limitations of the odds ratio in gauging the performance of a diagnostic, prognostic, or screening marker. Am J Epidemiol 159:882-890, 2004 (Pubitemid 38657490)